Request Quote

Applications of Q-PCR and DNA Sequencing in the Detection and Identification of Adventitious Agents



Priya Balachandran, PhD, Pharmaceutical Analytics Product Manager, Thermo Fisher Scientific

Priya Balachandran is the Product Manager in the Pharma Analytics business group. Priya has extensive experience in the area of microbiology and molecular biology. She has a PhD in microbiology from University of Alabama at Birmingham followed by a post-doctoral fellowship at University of California at San Francisco. She joined Life Technologies, now part of Thermo Fisher Scientific, in 2007 as an R&D scientist in the applied markets group, where she led multiple assay and sample prep product development projects for validated food safety testing and pharmaceutical markets. She began her product management role in late 2011, and manages the residual DNA testing portfolio as well as the microbiology portfolio, which includes the MicroSEQ^® ID system and the ViralSEQ^™ assays for the Pharma Analytics business unit within bioproduction.

Webinar Info

Viral contamination, including MMV and Vesivirus, is a potential threat to mammalian cell culture manufacturing processes. Many cell culture manufacturing facilities have been negatively impacted following contamination with these viruses.

In this session, you will be introduced to the Detection Kit offering:

• Detection of all known MMV or Vesivirus strains
• Specific, with no cross-reactivity with unrelated DNA
• And incorporating PrepSEQ® Nucleic Acid Extraction Kit, which is optimized for highly efficient DNA recovery

Genotypic testing methods, such as the sequencing approach utilized by the MicroSEQ^® Rapid Microbial Identification System in identification of bacteria and fungi. Based on proven DNA sequencing technologies, you will learn the benefits of this system, including:

• Minimize failed IDs, with “right-the-first-time-accuracy” to the species level
• Less confusion with ambiguous results with comprehensive validated libraries for bacteria and fungi
• Return on investment, due to reduced re-testing and reduced dependency on outside services.

Register and watch the webinar now

Please fill out the following form before viewing this webinar. Fields marked with an asterisk are required.

• Name
  First Name *

  Last Name *

  Please enter your first and last name.

• E-mail Address *

  Please enter the e-mail address you would like to be contacted at.

• Company *

  Please enter the name of the company or institution you work at.

• City & Country
  City *

  Select Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antigua And Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia And Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, The Democratic Republic of the Cook Islands Costa Rica Côte D'Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic East Timor Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican State) Honduras Hong Kong Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakstan Kenya Kiribati Korea, Democratic People's Republic of (North Korea) Korea, Republic of (South Korea) Kosovo Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macau Macedonia, The Former Yugoslav Republic Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States Of Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory, Occupied Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena Saint Kitts and Nevis Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent And The Grenadines Samoa San Marino Sao Tome And Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard And Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Togo Tokelau Tonga Trinidad And Tobago Tunisia Turkey Turkmenistan Turks And Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States United States Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Viet Nam Virgin Islands, British Virgin Islands, United States Wallis And Futuna Western Sahara Yemen Zambia Zimbabwe Country *

  Please enter your mailing address.

• Area of Bioprocessing *
  Upstream (i.e. cell line development, cell culture, cell therapy)Downstream (i.e. purification, chromatography, pre-packed process scale columns)

  Pharma Microbiology (i.e. QC micro)Biopharma Process Analytics (i.e. bacterial/fungal id, mycoplasma detection, micro virus detection)
• The contaminants you currently test for are (check all that apply): *
  MycoplasmaMouse minute virusVesivirus

  Other virusesNot presently testing for contaminants, but will have a need in the near future
• If you checked "Other Viruses" above, please list all:
• Which of the following impurities do you currently analyze? *
  Residual host cell DNA testingResidual Protein AHost Cell Proteins
• If you checked "Residual host cell DNA testing" above, please check all that apply
  CHOE.coliMDCKHuman

  PicchiaVeroOther
• If you checked "Other" above, please list all